Glioblastoma Multiforme (GBM) research hub

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

This study is testing two new drugs, avutometinib and defactinib, alone and with temozolomide, for people with aggressive brain tumours like glioblastoma. It aims to see if they are safe and can shrink tumours, particularly in patients with specific genetic changes.

5G-EMERALD: Amivantamab in Malignant Brain Tumours

This study, called 5G-EMERALD, is testing a new drug called amivantamab for people with certain types of aggressive brain tumours. It aims to see if the drug is safe and if it helps shrink tumours, especially in patients whose tumours have a specific genetic feature.

5G-PEARL: Paxalisib in Malignant Brain Tumours

This study, 5G-PEARL, looks at combining two drugs, paxalisib and temozolomide, for people with aggressive brain tumours. It aims to see if this combination is safe and helps shrink tumours. This research could lead to better treatments for these types of cancer.

A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy